SCOPE
Scar formation and fibrosis are common outcomes following injury to the skin. The healing process culminates in a new and intact cutaneous barrier, but fails to reestablish the structure and function of unwounded skin. Damage to the skin sets in motion the reparative process, during which prompt wound closure must be balanced against the need for continuation of function. 1 The earliest step of this progressive sequence is hemostasis, with repair then proceeding through subsequent inflammatory, granulation tissue deposition, and scar remodeling phases. Each step is orchestrated by intercellular interactions, as well as the production and release of signaling molecules necessary for recruiting the various cells involved in the protection, repair, and maturation of the healing tissue.
The wound healing process has been studied extensively in skin and is being increasingly investigated in other tissues. The heart proceeds through a reparative process similar to skin after injuries such as myocardial infarction (MI) or those resulting from cardiac surgery. 2 The maintenance of cardiac pumping function and the effective coordination of repair processes is an even more critical balance to strike following injury to the heart. A flawed repair could increase the susceptibility of the beating heart to rupture. Excess scarring of myocardial tissues may lead to disruptions in electrical conductivity and increase the susceptibility of the heart to arrhythmias. Fibrosis is also intimately linked to ventricular dilation, intractable declines in contractile function, and eventual death from heart failure. Unfortunately, humans have a limited capacity to regenerate tissues and organs without fibrosis. As such, much ongoing research is focused on developing strategies to prevent excess scar deposition and to regenerate normal structure and mechanical function of damaged tissues.
TRANSLATIONAL RELEVANCE
A potential therapy targeting scar fibrosis based on the gap junction protein connexin43 (Cx43) is described. Cx43 has been implicated in the spread of injury signals in skin, heart, and neural tissues, modulation of TGFb signaling, and ischemic preconditioning/cardioprotection.
2 Studies in healing skin wounds on mice have shown decreased levels and phosphorylation of Cx43 at wound edges and decreases in gap junction intercellular communication at acute time points after wounding. [1] [2] [3] [4] In mice expressing no or reduced levels of Cx43, skin wounds closed more quickly and MI injuries were smaller than in wildtype animals.
CLINICAL RELEVANCE
Cutaneous injuries resulting in excess scarring and the subsequent reduced function of skin are significant continuing clinical problems. Mechanical strength of these wounds is never completely restored. Studies examining surgical wounds have shown that by 1 year post-surgery, a maximum of 70-80% tensile strength is achieved. 5 MI occurs in over 1.2 million patients per year in the United States. 6 MI causes cardiac tissue necrosis and fibrosis, and may eventually lead to heart failure. Deadly cardiac arrhythmias can be also prompted by injury-induced fibrosis, and by the attendant reorganization of gap junctions in the damaged heart tissue.
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EXPERIMENTAL MODEL OR MATERIAL: ADVANTAGES AND LIMITATIONS
Mouse and swine models have been used extensively to study wound healing; the former due to its affordability and ease of use, the latter due to the similarity of porcine dermal structure to human skin. Mice provide an affordable and simple model for wound healing-though the loose skin and inflammatory response of mice differ somewhat from humans. As noted in Ghatnekar et al. 2009 , the relative thickness of porcine skin has the advantage of enabling elements of histoarchitecture such as subcutaneous complexity in vascular pattern to be more easily resolved and assessed for regeneration than in rodent models. 10 In our studies, full thickness incisional and excisional wounds of controlled size were created in the dermis of mice and swine. Pluronic gel (20%), with or without aCT1, was applied to the injuries created. Injuries were observed for several days to assess healing.
Our lab developed a mouse model of MI in which a liquid nitrogen-cooled cryo-probe was used to create a non-transmural injury on the left ventricle (LV) of the mouse heart. 11 The approach was based on a method described by Van The mechanism promoting cell death in our model differs from an MI in humans (and other animal models) in which arterial occlusion (or ligation) leads to ischemic death of myocardial tissue. However, this is weighed against the benefit of a model providing a reproducible wound to the ventricle from which most mice survive. Improved survival increases sample size, and a repeatable wound geometry provides increased confidence in the identification of statistically significant structural and functional endpoints. This experimentally attractive combination of attributes is typically not possible with experimental models such as coronary arterial ligation, which produce injuries that vary widely in size and shape and generally result in high mortality rates following the procedure.
The need for procedures enabling normalization of initial wounded areas such as those predicting ''myocardial area at risk'' is also obviated in our freeze-injury model, as the initial injury size is determined with precision by timed application of a cryo-probe of set dimension. Nonetheless, once confidently identified in the cryo-injury model, the subset of responsive endpoints can be validated in more clinically relevant myocardial injury models such as arterial ligation, radiofrequency ablation, or surgical wounding of the heart.
DISCUSSION OF FINDINGS AND RELEVANT LITERATURE
Gap junctions were first discovered in heart because of their ability to transmit electrical signals between cells. 2, 13 Gap junctions are responsible for the transmission of small (< 1000 Da) intercellular signaling molecules and conduct the ion transients responsible for cell-to-cell propagation of the cardiac action potential. They are composed of two hexameric hemichannels of connexins, each from an adjacent cell. Gap junctions in the healthy human ventricle are preferentially localized at the intercalated disc between cardiomyocytes and are composed of the gap junction protein Cx43.
Cx43 in dermal wound healing
Gap junctions in skin are thought to be responsible for intercellular spread of injury signals, inflammation, re-epithelialization, wound closure, and scarring. 1, 2, [13] [14] [15] [16] Cx43 is expressed in the dermal and epidermal layers of the skin 3,4,17-19 and has been previously reported as a target in dermal wound healing. 4, 19 Downregulation of Cx43 mRNA by antisense in mouse led to accelerated healing of skin wounds, 4 increased TGFb1 expression, increased fibroblast proliferation and motility in vitro, and an increase in granulation tissue formation in vivo.
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Enhanced re-epithelialization of skin wounds was seen with this antisense treatment in a diabetic skin model in mouse. 20 The C-terminus of Cx43 is an important regulatory domain. 1, 13, 21 We previously reported on a 25 amino acid peptide comprised of an antennapedia cell internalization sequence linked to the CT-most nine amino acids of the full-length Cx43 CT domain. [22] [23] [24] This peptide, which we call aCT1, binds the postsynpatic density 95/discs large/zonula occludens-1 (PDZ) class II-binding domain of zonula occludens-1 (ZO-1), competitively inhibiting the interactions of endogenous Cx43 with ZO-1. ZO-1 is a member of the membrane-associated guanylate kinase protein family and interacts with actin and connexin proteins, among others. More recently, we have demonstrated that aCT1 treatment of injured tissue is associated with upregulation of protein kinase C-mediated phosphorylation of Cx43, 11, 25 which leads to a decrease in gap junction communication and may be protective.
Following incisional wounding of neonatal mice, application of aCT1 peptide led to faster wound closure, reduced inflammation and gaping, and healing with less scarring than control wounds over a 7-day period. 10 The aCT1 peptide also conferred benefit to excisional wounds in adult mice, as wounds closed faster, were less swollen and inflamed, and healed with less discoloration over a 10-day period. Treatment with aCT1 led to a decrease in inflammation compared to controls. 10, 26 Epidermal histoarchitecture of healed control excisional wounds in adult mice showed little complexity, as rete pegs were absent (Fig. 1) . aCT1-treated wounds demonstrated tissue structure closer to unwounded skin with a fourfold increase in rete pegs compared to controls. Swine is a wellaccepted model for wound healing since it has skin that is said to resemble that of humans. At 30 days post-wounding, aCT1-treated wounds in swine showed a large number of rete pegs, significantly reduced granulation tissue area, and partial restoration of dermal vascular pattern compared to control wounds.
Strips of skin excised from mice at 1 and 3 months post-injury were extended to breaking to examine the mechanical properties of wounded tissue. In this type of test, failure of the tissue occurs at the weakest point-usually within the healed wound or at the interface between scar and CONNEXIN43 AND HEALING IN THE SKIN AND HEART normal tissue. At 1 month, aCT1-treated wounds were not significantly stronger or more extensible than control wounds (Fig. 1) . However, with ongoing scar remodeling by 3 months, significant improvements in the tensile strength and extensibility of healed wounds were found. Indeed, the strain-to-failure of aCT1-treated wounds approximated 90% that of unwounded skin, while the strain-to-failure of control wounds was only 60% of normal skin at failure. 
Cx43 in cardiac injury repair
Cx43 is abundant in the heart and is responsible for electrical conduction between cardiomyocytes. When the heart sustains injury, as occurs during myocardial infarction (MI), some hallmarks of the dermal wound-healing response occur, including fibrosis. Since fibrosis in the IBZ disrupts normal tissue and gap junction organization, this can lead to re-entrant arrhythmias. Another important change that occurs after MI is the lateralization of gap junctions in cardiomyocytes of the IBZ. 27 While it remains to be definitively established, gap junction lateralization is a strong candidate as a causal factor in the development of re-entrant arrhythmias. 28, 29 Since we know from in vitro data that aCT1 inhibited remodeling of gap junction size and cellular distribution, cryoinjured hearts were treated with aCT1 in order to establish whether the peptide could inhibit junctional remodeling and reduce the occurrence of re-entrant arrhythmias. It was found that aCT1-treated hearts were less likely to develop arrhythmias in response to programmed stimulation and had increased conduction velocity through the injured myocardium. These changes were found hand-in-hand with stabilization of Cx43 at the intercalated discs in the IBZ, as opposed to being laterally distributed between cardiomyocytes bordering the scar.
Injury-induced fibrosis is intimately linked to ventricular dilation, decline in cardiac contractile function, and eventual death from heart failure. To track the contractile function of the injured hearts, echocardiography was performed on mice just prior to surgery (baseline) and then again at 1, 4, 6, and 8 weeks following cryo-injury. Figure 2 illustrates a representative M-mode echocardiogram from a heart 8-weeks post-injury and treatment with aCT1 (Fig. 2) . Mean diastolic and systolic volumes were significantly decreased in the aCT1-treated group compared to control groups over an 8-week duration, with the most pronounced divergence in LV systolic and diastolic volumes between aCT1-treated and control groups occurring at 1 week. This reduction in ventricular dilation is indicative of improved mechanical function of peptide-treated hearts and may be prognostic that these animals were less likely to progress to heart failure as a consequence of their myocardial injuries.
INNOVATION
Scarring and lack of regeneration in cutaneous wounds continues to be a problem. aCT1 appears to 
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improve the ability of skin to heal regeneratively. Current clinical approaches to reduce scarring and improve wound healing typically include the use of wound dressings with a mix of growth factors that require repeated application. When applied at a single acute time point, aCT1 is able to speed up the wound healing process, reduce scar tissue area, and improve mechanical properties of the scar out as far as 3 months post-injury. 10 Our more recent studies in heart show that acute application of aCT1 to an experimental MI limits gap junctional remodeling in the IBZ and reduces arrhythmias. Peptide treatment is also associated with reduced ventricular dilation, a predictive indicator of heart failure. In heart, there presently are no other therapies in clinical practice that effectively reduce re-entrant arrhythmias or inhibit the progression to heart failure.
Technical innovations in the target articles include approaches to whole-mount assessment of initial inflammatory response in skin and a novel protocol for generating a repeatable nontransmural cryoinjury on the mouse left ventricle. Additionally, methodological approaches for delivery of the cell-permeant peptide aCT1 in vivo are provided, including formulation of the peptide in F127 pluronic thermogel and methylcellulose patches. The slight detergent properties of pluronic gel make it a good candidate for delivery of aCT1. The thermosensitive gel is applied as a liquid and easily conforms to the skin wound defect. It sets at body temperature and remains intact for several days after application. Methylcellulose can be made into adherent patches that remain immobilized on the heart surface and localize peptide to the injury for up to 48 hours after application.
CAUTION, CRITICAL REMARKS, AND RECOMMENDATIONS
While wound healing and scar mitigation therapies have seen significant advances over the years, we are some way from attaining perfectly regenerated tissue after wounding. So, there is still a need for the development of therapies that will have a higher clinical impact. Translation of new wound healing therapeutics to the clinic follows a long time course and approval of novel therapies is necessarily subject to numerous regulatory steps. In our animal pre-clinical models, aCT1 is delivered in a pluronic gel. To bring this therapy to the clinic, a clinically acceptable delivery vehicle for the peptide has been developed in compliance with good manufacturing practice. This formulation was developed and tested in an external application on skin wounds in a small phase I clinical trial of 48 human subjects by FirstString Research, Inc. and no safety issues were found. Larger phase II clinical trials for indications in skin are now set to proceed. While efficacy will be a focus of the phase II trials, safety monitoring is paramount. This is imperative since the pre-clinical work indicates efficacy as an anti-arrhythmic drug in the injured heart. Internal application of the peptide in the human heart would require a level of attention to potential safety issues that exceeds those of a less obligate organ or tissue.
FUTURE DEVELOPMENT OF INTEREST
Application of aCT1 to skin and heart has proven effective at reducing time to wound closure, reducing scar tissue area, and improving mechanical properties in the former, and reducing fibrosis and incidence of arrhythmias in the latter. Since this peptide primarily affects gap junctional organization in the cell, and gap junctional connexins are present in almost every tissue of the body, application of this peptide to other injured tissues may be warranted. When foreign materials are implanted into the body, significant amounts of fibrous encapsulation typically occurs, which can lead to failure of the implant or its extrusion from the body. Reducing the amount of fibrosis that oc-
TAKE-HOME MESSAGE Basic science advances
Wound healing in skin and heart in pre-clinical animal models can be improved through modulation of the gap junction protein connexin43.
Gap junction organization and associated electrical properties can be improved in the injury border zone of the heart post-MI in animal models.
Clinical science advances Scar size can be reduced and mechanical properties of skin can be improved with application of aCT1 after skin wounding.
Arrhythmias and left ventricular dilation in an experimental model of MI can be reduced by acute application of aCT1 peptide.
Relevance to clinical care
Healing of cutaneous wounds, including scar mitigation and diabetic or venous ulcers, may be improved by therapies based on Cx43 C-terminus mimetic peptides.
Ongoing research on these mimetic peptides may also eventually lead to novel treatment approaches of the presently intractable problem of heart failure.
curs in these situations is a noteworthy goal. Cx43 has also been shown to play an important role in skeletal muscle regeneration, as it is expressed early in regeneration of injured muscle, but its expression is decreased at later time points. Aiding the regeneration of skeletal muscle may be possible through modulation of connexins in this tissue. As fibrosis is such a ubiquitous feature of the wound healing response in humans, targeting Cx43 function following damage to brain, spinal cord, and cornea are additional important injury scenarios that warrant further investigation.
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